Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents.

ABSTRACT:

Background

Highly effective direct antiviral agents (DAAs) for hepatitis C virus (HCV) were introduced recently. Their utilisation has been limited by high cost and low access to care.

Aim

To describe the effect of DAAs on HCV treatment and cure rates in the United States Veterans Affairs (VA) national healthcare system.

Methods

We identified all HCV antiviral treatment regimens initiated from 1 January 1999 to 31 December 2015 (n = 105 369) in the VA national healthcare system, and determined if they resulted in sustained virological response (SVR).

Results

HCV antiviral treatment rates were low (1981-6679 treatments/year) in the interferon era (1999-2010). The introduction of simeprevir and sofosbuvir in 2013 and ledipasvir/sofosbuvir and paritaprevir/ombitas

SUBMITTER: Moon AM 

PROVIDER: S-EPMC5849458 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature